These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21976975)

  • 1. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
    Ding B; Wu X; Fan W; Wu Z; Gao J; Zhang W; Ma L; Xiang W; Zhu Q; Liu J; Ding X; Gao S
    Int J Nanomedicine; 2011; 6():1991-2005. PubMed ID: 21976975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.
    Ding B; Zhang W; Wu X; Wang J; Xie C; Huang X; Zhan S; Zheng Y; Huang Y; Xu N; Ding X; Gao S
    Oncotarget; 2016 Aug; 7(35):57160-57170. PubMed ID: 27494835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
    Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
    Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
    Faião-Flores F; Quincoces Suarez JA; Fruet AC; Maria-Engler SS; Pardi PC; Maria DA
    PLoS One; 2015; 10(3):e0118702. PubMed ID: 25742310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
    Engesæter B; Engebraaten O; Flørenes VA; Mælandsmo GM
    PLoS One; 2012; 7(9):e45492. PubMed ID: 23029050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
    Lillehammer T; Engesaeter BO; Prasmickaite L; Maelandsmo GM; Fodstad O; Engebraaten O
    J Gene Med; 2007 Jun; 9(6):440-51. PubMed ID: 17410615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
    Najar HM; Dutz JP
    J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
    Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
    Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells.
    Pei J; Su Z; Zeng X; Zhong Y; Zhang Y; Yang Y; Lu Q; Li J; Deng Y
    BMC Complement Med Ther; 2023 Apr; 23(1):111. PubMed ID: 37024907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
    Huncharek M; Caubet JF; McGarry R
    Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The curcumin analog DM-1 induces apoptotic cell death in melanoma.
    Faião-Flores F; Suarez JA; Maria-Engler SS; Soto-Cerrato V; Pérez-Tomás R; Maria DA
    Tumour Biol; 2013 Apr; 34(2):1119-29. PubMed ID: 23359272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
    Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
    J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
    Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM
    Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
    Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy.
    Xiong W; Guo Z; Zeng B; Wang T; Zeng X; Cao W; Lian D
    Front Bioeng Biotechnol; 2022; 10():847901. PubMed ID: 35252156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sonodynamic Therapy Using Dacarbazine-Loaded AuSiO
    Esmailzadeh A; Shanei A; Attaran N; Hejazi SH; Hemati S
    Ultrasound Med Biol; 2022 Jun; 48(6):1131-1142. PubMed ID: 35307236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
    Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
    Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
    Nagane M; Shimizu S; Mori E; Kataoka S; Shiokawa Y
    Neuro Oncol; 2010 Jul; 12(7):687-700. PubMed ID: 20511188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine.
    Thangasamy T; Sittadjody S; Limesand KH; Burd R
    Cell Oncol; 2008; 30(5):371-87. PubMed ID: 18791269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
    Risberg K; Fodstad O; Andersson Y
    J Immunother; 2010 Apr; 33(3):272-8. PubMed ID: 20445347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.